Evotec SE (0IRF.L)

25.91 +0.48 (+1.88%) At close: 06:18PM BST

Evotec SE

Essener Bogen 7
Hamburg 22419
Germany
49 40 560 81 0
https://www.evotec.com

Sector(s): 
Industry: 
Full-time employees: 5,061

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Mario Polywka DPHIL, Ph.D.	Interim CEO, Member of the Management Board & Member of the Supervisory Board	N/A	N/A	1963
Dr. Werner Lanthaler M.B.A., MPA, Ph.D.	Member of Management Board	1.32M	N/A	1968
Dr. Cord Dohrmann Ph.D.	Chief Scientific Officer & Member of Management Board	804k	N/A	1964
Dr. Craig Johnstone Ph.D.	COO & Member of Management Board	712k	N/A	1970
Dr. Matthias Evers Ph.D.	Chief Business Officer & Member of Management Board	636k	N/A	1973
Ms. Laetitia Rouxel	CFO & Member of Management Board	N/A	N/A	1974
Ms. Anja Bosler	Principal Accounting Officer and Senior Vice President of Group Accounting	N/A	N/A	N/A
Mr. Volker Braun	Executive VP and Head of Global Investor Relations & ESG	N/A	N/A	N/A
Dr. Christian Dargel	EVP Global Head of Legal & Compliance	N/A	N/A	N/A
Gabriele Hansen	Senior VP & Head of Global Corporate Communications & Marketing	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Corporate governance

Evotec SE’s ISS governance QualityScore as of 1 April 2024 is 6. The pillar scores are Audit: 4; Board: 4; Shareholder rights: 1; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.